1816 Preliminary safety results from PERUSE, a study of 1436 patients (pts) treated with first-line pertuzumab (P) combined with trastuzumab (H) and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)

David Miles, Fabio Puglisi, Eva Ciruelos, Tamar Peretz‐Yablonski, Kathryn C Moreno, Eleonora Restuccia, S. Lasserre, Thomas Bachelot

European Journal of Cancer · 2015 · 12 citations · 0 references

Concepts